UK Life Sciences Real Estate: Where to Invest Beyond the Golden Triangle

Significant life sciences real estate investment opportunities exist beyond the traditional ‘Golden Triangle’ of London-Oxford-Cambridge. Emerging hubs such as Manchester, Birmingham, and Sheffield offer compelling prospects, driven by world-class university research, NHS anchor institutions, and a structural undersupply of specialised laboratory and R&D facilities. For investors, these clusters present a chance to access a high-growth sector at a potentially lower entry cost and with less competition than in the overheated South East.

TL;DR: Investing in Regional Life Sciences

• Structural Undersupply: Demand for lab space in key regional cities far outstrips current and pipeline supply, creating strong rental growth potential.
• University Anchors: Leading research universities in cities like Manchester, Birmingham, and Leeds act as powerful magnets for talent, funding, and corporate-academic collaboration.
• Lower Entry Costs: Land and asset values in emerging hubs are considerably lower than in the Golden Triangle, allowing for potentially higher yielding development and investment strategies.
• Government & Private Funding: Substantial public and private investment is flowing into regional science and technology ecosystems, de-risking development and fuelling occupier demand.
• Tenant Stickiness: The high cost of fitting out labs and the integration with local innovation ecosystems result in high tenant retention rates and long lease terms.

—

The Overheating Golden Triangle

The UK life sciences sector is a global success story, attracting record levels of venture capital and corporate investment. Historically, this activity has been concentrated in the Golden Triangle, the area encompassing London, Oxford, and Cambridge. This concentration has created a hyper-competitive real estate market characterized by:

• Compressed Yields: Prime lab yields in Cambridge and Oxford are among the lowest in the UK commercial property market, often falling below 4.5%.
• Intense Competition: Bidding for development sites and existing assets is fierce, involving major institutional investors, REITs, and sovereign wealth funds.
• Vacancy Rates Near Zero: According to data from firms like JLL and Savills, vacancy for fitted lab space in core Golden Triangle locations is functionally zero, pushing rents to record highs.

While the Golden Triangle remains a critical global hub, its market dynamics are forcing occupiers and investors to look for growth opportunities elsewhere. This geographical diversification is the single most important emerging trend in the UK life sciences real estate market today.

Emerging UK Life Sciences Hubs to Watch

A number of regional cities are developing critical mass in life sciences, backed by academic excellence, public sector support, and growing private investment. These clusters offer a diverse range of specialisms, from advanced therapies and diagnostics to health data and medical technologies. The table below provides a snapshot of the most prominent emerging hubs.

| City | Key Institutions & Anchors | Key Specialisms | Indicative Prime Rent (Fitted Lab, per sq ft) | Indicative Net Initial Yield | Investment Note | |————–|——————————————————————–|———————————————————–|———————————————|——————————|————————————————————————————–| | Manchester | University of Manchester, Manchester Science Park, Health Innovation Manchester | HealthTech, Genomics, Advanced Materials, Oncology | £45 – £55 | 5.00% – 5.50% | Europe’s largest clinical-academic campus. Strong track record of public-private partnership. | | Birmingham | University of Birmingham, Birmingham Health Partners, Precision Health Technologies Accelerator | MedTech, Clinical Trials, Cell & Gene Therapy | £35 – £45 | 5.25% – 5.75% | Large and diverse patient population for clinical trials. Major regeneration projects underway. | | Leeds | University of Leeds, Leeds Teaching Hospitals NHS Trust, Nexus | Health Data, AI in Medicine, Surgical Technologies | £30 – £40 | 5.50% – 6.00% | A leading centre for health data research, leveraging strong NHS and university links. | | Sheffield | University of Sheffield, AMRC, Sheffield Teaching Hospitals | Advanced Manufacturing (MedTech), Gene Therapy, Neuroscience | £28 – £35 | 5.75% – 6.25% | World-leading expertise in advanced manufacturing applicable to medical device production. | | Nottingham | University of Nottingham, BioCity, MediCity | Drug Discovery, MedTech, Diagnostics | £28 – £35 | 5.75% – 6.25% | Home to BioCity, one of the UK’s most successful life science incubator networks. |

Note: Rents and yields are indicative estimates for prime, newly developed, or refurbished fitted lab space as of late 2023/early 2024 and are subject to market fluctuation. Source: McGardens’ Research, compiled from market data by Savills, CBRE, and Colliers.

Key Demand Drivers in Regional Clusters

The growth of these regional hubs is not speculative; it is underpinned by powerful, long-term structural drivers that create sustained demand for specialised real estate.

Core Demand Statistics

• Venture Capital Investment: UK Biotech and HealthTech firms raised over £6 billion in 2022, with an increasing proportion directed towards companies based outside the South East. (Source: BioIndustry Association, 2023)
• University Spin-outs: The UK’s leading research universities, including Manchester and Birmingham, collectively generate hundreds of spin-out companies annually, forming a primary source of demand for incubator and grow-on lab space. (Source: Beauhurst, 2023)
• Constrained Supply: Across key regional markets, JLL estimates there is over 1.5 million sq ft of active demand for lab space, against a vacancy rate for suitable existing stock of less than 2%. (Source: JLL Research, 2023)
• Government Funding: The government has committed billions through initiatives like the UK Research and Innovation (UKRI) fund and the Life Sciences Investment Programme to support R&D and infrastructure development across the country.

These factors create a landlord-favourable environment where demand significantly outweighs supply, supporting rental growth and asset value appreciation over the long term.

Investment Models: How to Access the Sector

Investing in life sciences real estate requires a more specialised approach than traditional commercial property. There are several routes for family offices and institutional capital to gain exposure.

Checklist: Routes to Market

1. [ ] Direct Development: Acquiring land and developing new science parks or standalone lab buildings from the ground up. This offers the highest potential returns but carries development risk and requires significant expertise. Often undertaken in joint venture with a specialist developer.
2. [ ] Asset Repurposing: Acquiring under-utilised commercial or light industrial assets in appropriate locations and converting them for lab use. This can be faster and more cost-effective than new-builds but presents significant technical challenges regarding floor loading, ceiling heights, and ventilation.
3. [ ] Forward Funding/Forward Commitment: Agreeing to acquire a development upon its completion. This mitigates development risk for the investor while providing the developer with crucial capital. This model is increasingly popular with institutional investors.
4. [ ] Sale and Leaseback: Acquiring a facility directly from a life sciences occupier and simultaneously leasing it back to them on a long-term contract. This provides immediate income and a high-quality covenant but offers less scope for value-add asset management.
5. [ ] Joint Ventures with Universities: Forming public-private partnerships (PPPs) with universities to develop and manage innovation campuses. This provides access to a pipeline of spin-out tenants and deep integration into the local ecosystem.

Standard Commercial vs. Life Sciences Real Estate

Investors must understand the fundamental differences between life sciences assets and conventional commercial property like offices or logistics. The operational requirements and tenant relationships are distinct.

— Comparison Box: Office vs. Lab Space

Standard Office Building

• Fit-out: Primarily aesthetic and functional (desks, meeting rooms, kitchen). Tenant-funded and relatively low cost.
• Infrastructure: Standard HVAC, power, and data connectivity.
• Lease Term: Increasingly flexible, with break clauses common at 3-5 years.
• Tenant Stickiness: Relatively low. Relocation is disruptive but manageable.
• Valuation: Based on standard office market rents and yields.

Life Sciences Lab Space

• Fit-out: Highly technical and expensive (e.g., fume hoods, specialised ventilation, piped gases, waste management). Often funded by the landlord as part of the base build, costing £150-£300+ per sq ft.
• Infrastructure: Enhanced power and data resilience, significant floor-loading capacity, increased ceiling heights (4m+ slab-to-slab), and advanced air handling (100% fresh air).
• Lease Term: Typically longer, from 10 to 25 years, to amortise the high fit-out cost.
• Tenant Stickiness: Very high. The cost and disruption of moving a lab, coupled with regulatory re-certification (e.g., from the MHRA), make tenants reluctant to relocate.
• Valuation: Based on specialist rents and a higher ‘stickiness’ premium, but also requires factoring in higher capex and maintenance.

—

McGardens’ View: A Structural Growth Story for Patient Capital

For family offices and institutional investors, the UK’s regional life sciences real estate sector represents a compelling structural growth story, not a cyclical opportunity. It offers diversification away from mainstream assets like Build-to-Rent (BTR) and logistics, which have become crowded trades. The investment thesis is predicated on the UK’s non-negotiable strategic importance in global science and medicine.

The long leases, often with inflation-linked rent reviews, provide the kind of secure, long-term income streams that are highly attractive to institutional capital. Furthermore, the high tenant stickiness, born from the prohibitive cost of relocation, provides a defensive quality that is hard to replicate in other sectors.

However, this is not a passive investment. Success requires partnering with specialist developers and asset managers who understand the technical nuances of lab specification and the unique ecosystem-driven nature of tenant demand. The risks are real: high upfront capital expenditure, potential for obsolescence if technology changes, and the requirement for deep local knowledge to identify the next successful innovation cluster.

For investors with patient capital and a tolerance for higher upfront complexity—such as GCC investors or family offices with a multi-generational outlook—the reward is a stake in the UK’s innovation infrastructure. This involves capturing both rental income and significant capital appreciation as these regional hubs mature, moving from emerging clusters to established centres of excellence.

Key Takeaways

• Diversification: Life sciences offers a powerful diversifying agent within a UK real estate portfolio.
• Supply Scarcity is Structural: The gap between demand and supply for lab space will not be closed quickly, underpinning rental growth forecasts.
• Expertise is Non-Negotiable: Investors must partner with specialists in development, asset management, and leasing to succeed.
• Patient Capital Wins: The highest returns will be generated by those who can commit capital to development and asset creation over a 5-10 year horizon, rather than simply acquiring stabilised assets at compressed yields.

—

FAQ: Investor Questions Answered

How do life sciences yields in regional cities compare to the Golden Triangle?

Yields in emerging hubs like Manchester or Birmingham are typically 75 to 150 basis points higher than in the core Golden Triangle. A prime lab in Cambridge might yield 4.5%, whereas a comparable asset in Manchester could offer a net initial yield of 5.25% to 5.50%. This spread reflects the perceived maturity of the market and the higher risk profile of regional clusters, but it also presents a significant opportunity for yield-seeking investors.

What are the main risks of repurposing an office building for lab use?

The primary risks are technical and financial. Many office buildings lack the requisite floor-to-ceiling heights, floor loading capacity, and space for robust ventilation systems required for labs. Retrofitting these can be prohibitively expensive and complex, often erasing the initial cost-saving advantage over a new build. A thorough technical due diligence process is absolutely critical to mitigate this risk and ensure the building is genuinely suitable for conversion.

How important is government funding to the success of regional hubs?

Government funding is extremely important as a catalyst, but it is not the sole driver. Public investment from bodies like UKRI de-risks early-stage discovery and funds the core university infrastructure that attracts private companies and venture capital. This creates a virtuous cycle where public seed funding stimulates a private market. Successful clusters are those that leverage initial government support to build a self-sustaining commercial ecosystem, which is what we are seeing in Manchester and Birmingham.

What lease structures are common in the life sciences sector?

Leases are typically longer than in the office sector, commonly ranging from 10 to 25 years. They often include upward-only rent reviews, which may be linked to an inflation index like RPI or CPI, providing a hedge against inflation. For incubator and smaller scale-up spaces, more flexible leases (3-5 years with break options) may be offered, but the landlord will factor the higher risk and management intensity into the rent.

How does this compare to investing in Purpose-Built Student Accommodation (PBSA)?

Both sectors are underpinned by universities, but they serve different parts of the ecosystem. PBSA houses the student talent pipeline, while life sciences real estate houses the research and commercialisation that comes out of it. Life sciences has higher barriers to entry, higher capex, and more specialised tenants. In return, it can offer longer and more secure income streams and potentially greater capital growth due to the immense scarcity of specialised supply, whereas the PBSA market is more mature.

Is it better to invest directly in an asset or through a specialist fund?

This depends on the investor’s scale, expertise, and risk appetite. Direct investment offers more control and potentially higher returns but requires significant in-house or mandated expertise in life sciences real estate. For many family offices and smaller institutions, investing via a specialist fund managed by an experienced team is a more prudent approach. It provides diversification across several assets and locations and leverages the manager’s expert knowledge in sourcing, developing, and managing these complex properties.